InsiderTrades.com logo
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold   |   Ad
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.

Preetam Shah Biography and Net Worth

CFO of Cidara Therapeutics
  • LinkedIn
  • Phone
  • Email
  • Website


Founder of Saisarva LLC, Preetam Shah presently is Chief Financial & Business Officer at Cidara Therapeutics, Inc.

In the past Dr. Shah was Vice President-U.S. Operations & Investments at Reliance Capital Usa Ventures LLC, Chief Financial Officer, Treasurer & Executive VP of Brainstorm Cell Therapeutics, Inc., Director-Healthcare Investment Banking at Barclays Capital, Inc., Director-Healthcare Investment Banking at Lordes Capital Ltd. and Vice President-Healthcare Investment Banking at Canaccord Genuity, Inc.

Preetam Shah received an MBA from The Wharton School of the University of Pennsylvania and a doctorate from the University of Mississippi Medical Center.

What is Preetam Shah's net worth?

The estimated net worth of Preetam Shah is at least $203,798.40 as of March 11th, 2024. Dr. Shah owns 11,360 shares of Cidara Therapeutics stock worth more than $203,798 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Shah may own. Additionally, Dr. Shah receives an annual salary of $577,850.00 as CFO at Cidara Therapeutics. Learn More about Preetam Shah's net worth.

How old is Preetam Shah?

Dr. Shah is currently 51 years old. There are 5 older executives and no younger executives at Cidara Therapeutics. The oldest executive at Cidara Therapeutics is Dr. Jeffrey L. Stein Ph.D., President, CEO & Executive Director, who is 69 years old. Learn More on Preetam Shah's age.

What is Preetam Shah's salary?

As the CFO of Cidara Therapeutics, Inc., Dr. Shah earns $577,850.00 per year. There are 2 executives that earn more than Dr. Shah. The highest earning executive at Cidara Therapeutics is Dr. Leslie Tari Ph.D., Chief Scientific Officer, who commands a salary of $845,100.00 per year. Learn More on Preetam Shah's salary.

How do I contact Preetam Shah?

The corporate mailing address for Dr. Shah and other Cidara Therapeutics executives is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. Cidara Therapeutics can also be reached via phone at (858) 752-6170 and via email at [email protected]. Learn More on Preetam Shah's contact information.

Has Preetam Shah been buying or selling shares of Cidara Therapeutics?

Preetam Shah has not been actively trading shares of Cidara Therapeutics during the last quarter. Most recently, Preetam Shah sold 946 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $13.40, for a transaction totalling $12,676.40. Following the completion of the sale, the chief financial officer now directly owns 11,360 shares of the company's stock, valued at $152,224. Learn More on Preetam Shah's trading history.

Who are Cidara Therapeutics' active insiders?

Cidara Therapeutics' insider roster includes Neil Abdollahian (Insider), Paul Daruwala (COO), Timothy Franson (Director), Brady Johnson (VP), Jessica Oien (General Counsel), Preetam Shah (CFO), Jeffrey Stein (CEO), and Leslie Tari (Insider). Learn More on Cidara Therapeutics' active insiders.

Are insiders buying or selling shares of Cidara Therapeutics?

In the last twelve months, Cidara Therapeutics insiders bought shares 1 times. They purchased a total of 8,000 shares worth more than $105,680.00. In the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 3,944 shares worth more than $51,223.36. The most recent insider tranaction occured on September, 11th when insider Taylor Sandison sold 924 shares worth more than $10,755.36. Insiders at Cidara Therapeutics own 7.6% of the company. Learn More about insider trades at Cidara Therapeutics.

Information on this page was last updated on 9/11/2024.

Preetam Shah Insider Trading History at Cidara Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2024Sell946$13.40$12,676.4011,360View SEC Filing Icon  
3/13/2023Sell332$30.60$10,159.207,407View SEC Filing Icon  
9/19/2022Sell782$15.40$12,042.807,539View SEC Filing Icon  
11/12/2021Buy1,000$30.80$30,800.00View SEC Filing Icon  
See Full Table

Preetam Shah Buying and Selling Activity at Cidara Therapeutics

This chart shows Preetam Shah's buying and selling at Cidara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cidara Therapeutics Company Overview

Cidara Therapeutics logo
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Read More

Today's Range

Now: $17.94
Low: $17.17
High: $18.98

50 Day Range

MA: $12.00
Low: $10.17
High: $15.63

2 Week Range

Now: $17.94
Low: $10.00
High: $24.40

Volume

271,372 shs

Average Volume

39,342 shs

Market Capitalization

$126.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold   |   Ad
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.